| abstract |
Embodiments of the disclosure relate to selectively substituted quinoline compounds of formula (I) that act as antagonists or inhibitors for Toll -like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis. |